Global Study on Volrustomig for Patients with Advanced Head and Neck Cancer After Chemoradiotherapy

Sponsor: AstraZeneca

Sponsor score: 40
Inactive

ClinicalTrials ID:NCT06129864

Provider View

This study is evaluating the effectiveness and safety of a new drug, volrustomig, compared to regular monitoring in patients with advanced head and neck cancer who have completed chemoradiotherapy and have not shown disease progression.

Patient Parameters

Program Overview

The purpose of this study is to determine if the drug volrustomig is effective and safe for patients with advanced head and neck squamous cell carcinoma (HNSCC) who have not had surgery and have completed chemoradiotherapy without their cancer getting worse. The study compares volrustomig to simply observing the patients' condition over time.

Eligibility Criteria

Inclusion Criteria

  • Diagnosed with advanced squamous cell carcinoma in specific areas of the head and neck, such as the throat, mouth, or voice box, without cancer spreading to other parts of the body.
  • Cancer must be classified as Stage III, IVA, or IVB according to specific medical guidelines.
  • Must have completed a combination of chemotherapy and radiation therapy aimed at curing the cancer within the last 12 weeks.

Exclusion Criteria

  • Diagnosed with head and neck cancer in areas not specified in the inclusion criteria, or with a type of cancer that is not squamous cell carcinoma.
  • Have more than one primary tumor.
  • Have remaining cancer that needs more treatment after completing chemoradiotherapy.
  • Had surgery to remove the cancer before starting chemoradiotherapy.
  • Cancer has returned at the time of screening.
  • Received only radiation therapy as the main treatment for their cancer.
  • Completed their last cancer treatment more than 12 weeks before joining the study.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.